Skip to main content
Clinical Trials/NCT07606404
NCT07606404RecruitingNot Applicable

Vitreoretinal Surgery for Full-Thickness Macular Hole: A Comparative Study of Ten Techniques

Kazakh Eye Research Institute1 site in 1 country120 target enrollmentStarted: May 25, 2026Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
120
Locations
1

Study Overview

Brief Summary

This study compares ten modern vitreoretinal surgical techniques for full-thickness macular hole repair. Participants will be randomly assigned to one of the surgical approaches during pars plana vitrectomy, using stratified randomization based on macular hole size to ensure balanced groups. The main goal is to determine which technique provides the highest anatomical closure rate on optical coherence tomography (OCT) and the best visual outcomes. Follow-up visits are scheduled at Day 7, Month 1, and Year 1 after surgery to assess OCT findings, visual acuity, safety outcomes, and the need for reoperation.

Detailed Description

Full-thickness macular hole is a vision-threatening condition that is commonly treated with pars plana vitrectomy (PPV) and internal limiting membrane (ILM) peeling. While standard approaches achieve high closure rates in many cases, outcomes may vary depending on macular hole size and OCT morphology, and advanced surgical strategies (e.g., different ILM flap configurations, adjunctive biologic augmentation, hydrodissection, or grafting techniques) are increasingly used in clinical practice.

This single-center, randomized, parallel-group interventional study will compare ten PPV-based surgical techniques for full-thickness macular hole repair. Eligible participants will include adults with full-thickness macular hole across a broad range of minimum linear diameter (MLD), including MLD <250 µm. After eligibility confirmation and informed consent, participants will be randomized to one of the ten procedure groups. Randomization will be stratified by macular hole size into five predefined MLD strata to ensure balanced distribution of hole sizes across all intervention groups. Postoperative care and follow-up procedures will be standardized across groups according to the study protocol.

Follow-up visits are scheduled at Day 7, Month 1, and Year 1 after surgery and will include clinical examinations and OCT imaging. The primary endpoint is anatomical macular hole closure on OCT at the prespecified primary time point. Secondary endpoints include best-corrected visual acuity (BCVA), OCT-based morphologic recovery parameters, intraoperative and postoperative complication rates, reoperation rates, and adverse event information through Year 1. The study aims to generate evidence to guide selection of surgical technique based on macular hole morphometric and clinical characteristics while maintaining patient safety.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adults aged ≥18 years.
  • Full-thickness macular hole (FTMH) eligible for pars plana vitrectomy (PPV).
  • Symptom duration ≤12 months.
  • Clear ocular media sufficient for high-quality OCT imaging.
  • No prior pars plana vitrectomy in the study eye.
  • No severe foveal atrophy on OCT.
  • Able and willing to comply with postoperative positioning and follow-up visits.
  • Written informed consent provided.

Exclusion Criteria

  • A. Etiology-Related / Secondary Macular Holes:
  • Traumatic macular hole.
  • High myopia with posterior staphyloma (axial length >28 mm and/or spherical equivalent ≤-8.0 D).
  • Diabetic tractional retinal detachment (TRD) or significant tractional maculopathy.
  • Retinal vascular occlusion-related macular hole.
  • Uveitis-related macular hole.
  • Advanced age-related macular degeneration (AMD) with foveal atrophy.
  • B. Prior Interventions:
  • Any prior pars plana vitrectomy in the study eye.
  • C. Ocular Conditions That May Affect Outcomes or Safety:
  • Active or recent ocular infection or inflammation (e.g., uveitis, endophthalmitis, keratitis).
  • Uncontrolled glaucoma (intraocular pressure >28 mmHg despite treatment).
  • Media opacity precluding adequate OCT (e.g., dense cataract or corneal opacity).
  • Geographic atrophy involving the fovea.

Investigators

Sponsor
Kazakh Eye Research Institute
Sponsor Class
Network
Responsible Party
Principal Investigator
Principal Investigator

Kairat Ruslanuly

Senior Scientific Researcher

Kazakh Eye Research Institute

Study Sites (1)

Loading locations...

Similar Trials